Minimal residual disease assessment in acute lymphoblastic leukemia by 4-color flow cytometry: Recommendations from the MRD Working Group of the Brazilian Society of Bone Marrow Transplantation

INTRODUCTION: The minimal residual disease (MRD) status plays a crucial role in the treatment of acute lymphoblastic leukemia (ALL) and is currently used in most therapeutic protocols to guide the appropriate therapeutic decision. Therefore, it is imperative that laboratories offer accurate and reli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikoma-Colturato, Maura R.V., Beltrame, Miriam P., Furtado, Felipe M., Pimenta, Glicinia, da Costa, Elaine Sobral, Azambuja, Ana Paula, Malvezzi, Mariester, Yamamoto, Mihoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446261/
https://www.ncbi.nlm.nih.gov/pubmed/33281111
http://dx.doi.org/10.1016/j.htct.2020.09.148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446261/
https://www.ncbi.nlm.nih.gov/pubmed/33281111
http://dx.doi.org/10.1016/j.htct.2020.09.148

Ejemplares similares